Related Experiment Video
Updated: Feb 27, 2026
10:12
Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers
Published on: September 19, 2022
2.9K
Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting
Christine Weiss1, Eduard Figueras1, Adina N Borbely1
1Organic and Bioorganic Chemistry, Department of Chemistry, Bielefeld University, PO Box 100131, 33501, Bielefeld, Germany.
Summary
Cryptophycins, potent anti-cancer peptides from cyanobacteria, target tubulin to halt cancer cell growth. Despite past toxicity, new conjugates offer promising targeted tumor therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Cryptophycins are cytotoxic macrocyclic depsipeptides from cyanobacteria.
- They exhibit potent antiproliferative activity by interacting with tubulin.
- This interaction disrupts microtubule dynamics, leading to cell-cycle arrest and apoptosis.
Purpose of the Study:
- To explore the potential of cryptophycins as anti-cancer agents.
- To understand their mechanism of action involving tubulin and microtubule dynamics.
- To investigate strategies for overcoming limitations like neurotoxicity and drug resistance.
Main Methods:
- Isolation and characterization of cryptophycins from cyanobacteria.
- In vitro assays to determine antiproliferative activity and potency compared to existing drugs.
- Studies on the interaction with tubulin and effects on microtubule polymerization.
- Evaluation of activity in multidrug-resistant cancer cell lines.
- Development of cryptophycin conjugates for targeted delivery.
Main Results:
- Cryptophycins demonstrate 100- to 1000-fold higher potency than paclitaxel and vinblastine.
- Their efficacy is not diminished by P-glycoprotein-mediated drug efflux.
- Cryptophycin-52 showed promise but was limited by neurotoxicity in clinical trials.
- Recent development of peptide and antibody conjugates for targeted cancer therapy.
Conclusions:
- Cryptophycins are highly potent anti-cancer compounds with a unique mechanism of action.
- Their effectiveness against multidrug-resistant cancers is a significant advantage.
- Targeted delivery strategies, such as conjugates, are crucial for improving their therapeutic index and overcoming toxicity.
- Further research into cryptophycin conjugates holds promise for advanced tumor therapy.
Related Concept Videos
02:34Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
01:10Drugs that Destabilize Microtubules
4.1K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.1K
01:15Drugs that Stabilize Microtubules
2.8K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:39Positive Regulator Molecules
7.0K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.0K
02:15M-Cdk Drives Transition Into Mitosis
6.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K